PROTALIX BIOTHERAPEUTICS INC (PLX) — insider trading
Health Care · NYSE American
PROTALIX BIOTHERAPEUTICS INC (PLX) has 38 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 1 open-market sale among the most recent 38 (latest 2026-09-03).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | Schwartz Aharon | Director | Grant / award / vesting (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-09-03 | Schwartz Aharon | Director | Grant / award / vesting (derivative) | 17,000 | — | $0 | Form 4 |
| 2026-09-03 | Forster Eliot | Director | Grant / award / vesting (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-09-03 | Forster Eliot | Director | Grant / award / vesting (derivative) | 17,000 | — | $0 | Form 4 |
| 2026-09-03 | Ben Zvi Shmuel | Director | Grant / award / vesting (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-09-03 | Ben Zvi Shmuel | Director | Grant / award / vesting (derivative) | 17,000 | — | $0 | Form 4 |
| 2026-09-03 | Bar-Shalev Amos | Director | Grant / award / vesting (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-09-03 | Bar-Shalev Amos | Director | Grant / award / vesting (derivative) | 17,000 | — | $0 | Form 4 |
| 2026-09-03 | Bashan Dror | Director, Officer (PRESIDENT AND CEO) | Grant / award / vesting (derivative) | 160,000 | — | $0 | Form 4 |
| 2026-09-03 | Bashan Dror | Director, Officer (PRESIDENT AND CEO) | Grant / award / vesting (derivative) | 320,000 | — | $0 | Form 4 |
| 2026-09-03 | Boudes Pol F | Director | Grant / award / vesting (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-09-03 | Boudes Pol F | Director | Grant / award / vesting (derivative) | 17,000 | — | $0 | Form 4 |
| 2026-09-03 | Melincoff Gwen A | Director | Grant / award / vesting (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-09-03 | Melincoff Gwen A | Director | Grant / award / vesting (derivative) | 17,000 | — | $0 | Form 4 |
| 2026-09-03 | Elze Christian | Director | Grant / award / vesting (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-09-03 | Elze Christian | Director | Grant / award / vesting (derivative) | 17,000 | — | $0 | Form 4 |
| 2026-09-03 | Naos Yaron | Officer (Sr. VP & COO) | Grant / award / vesting (derivative) | 56,000 | — | $0 | Form 4 |
| 2026-09-03 | Naos Yaron | Officer (Sr. VP & COO) | Grant / award / vesting (derivative) | 112,000 | — | $0 | Form 4 |
| 2025-12-19 | Bashan Dror | Director, Officer (PRESIDENT AND CEO) | Open-market purchase | 56,000 | $1.81 | $101.4K | Form 4 |
| 2025-11-18 | Bar-Shalev Amos | Director | Open-market sale | 168 | $1.87 | $314 | Form 4 |
| 2025-09-03 | Bashan Dror | Director, Officer (PRESIDENT AND CEO) | Grant / award / vesting (derivative) | 340,000 | — | $0 | Form 4 |
| 2025-09-03 | Bashan Dror | Director, Officer (PRESIDENT AND CEO) | Grant / award / vesting | 195,000 | — | — | Form 4 |
| 2025-09-03 | Naos Yaron | Officer (Sr. VP, Operations) | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2025-09-03 | Naos Yaron | Officer (Sr. VP, Operations) | Grant / award / vesting | 25,000 | — | — | Form 4 |
| 2025-09-03 | Bar-Shalev Amos | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2025-09-03 | Bar-Shalev Amos | Director | Grant / award / vesting | 7,500 | — | — | Form 4 |
| 2025-09-03 | Ben Zvi Shmuel | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2025-09-03 | Ben Zvi Shmuel | Director | Grant / award / vesting | 7,500 | — | — | Form 4 |
| 2025-09-03 | Schwartz Aharon | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2025-09-03 | Schwartz Aharon | Director | Grant / award / vesting | 7,500 | — | — | Form 4 |
| 2025-09-03 | Elze Christian | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2025-09-03 | Elze Christian | Director | Grant / award / vesting | 7,500 | — | — | Form 4 |
| 2025-09-03 | Boudes Pol F | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2025-09-03 | Boudes Pol F | Director | Grant / award / vesting | 7,500 | — | — | Form 4 |
| 2025-09-03 | Melincoff Gwen A | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2025-09-03 | Melincoff Gwen A | Director | Grant / award / vesting | 7,500 | — | — | Form 4 |
| 2025-09-03 | Forster Eliot | Director | Grant / award / vesting (derivative) | 15,000 | — | $0 | Form 4 |
| 2025-09-03 | Forster Eliot | Director | Grant / award / vesting | 7,500 | — | — | Form 4 |
Ask the chat about PLX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: PROTALIX BIOTHERAPEUTICS INC (PLX).
Last updated 2026-09-03 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.